However, in contrast to Sox9 LKO or YAP1 alone-mediated liver cancer studies, acute Sox9 disruption using the CRISPR/Cas9 system robustly repressed Akt-YAP1 cHCC-CCA formation, irrespective of tumor fate. The gene discussed is YAP1; the disease is neoplasm.